Esophageal Cancer Awareness Association

12/22/2025

12/20/2025

💜💜💜

12/15/2025

https://www.pilotonline.com/2025/12/07/virginia-beach-law-school-launches-singer-center-for-advocacy-in-tribute-to-attorney-battling-cancer/

Randy Singer is making sure that at least one of seven items on his bucket list — creating The Singer Center for Advocacy at Regent University’s School of Law — will come to fruition.

12/15/2025

https://seekingalpha.com/pr/20331020-innovent-announces-inclusion-of-seven-innovative-drugs-including-tyvyt-new-indication-and

SAN FRANCISCO and SUZHOU, China, Dec. 6, 2025/ PRNewswire/-- Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major....

12/14/2025

https://finance.yahoo.com/news/systematic-review-meta-analysis-confirms-120000633.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAADGoABlym9xzU7UXgA3p5zs3ZnmDbCraVEQLoIQSmeNUd84_wtmUuPowsLFX2mAFTsnXYKiORgIgJNU93jhjOq1JFDxXPgPL_l2KPTuf9UanY025heWBAQhZng54v4Y8x72HEx34GElqt4gHL_NaTe4TGs4tnGCXdL9yb_BSUPD1

Across multiple published studies, the test consistently identifies high-risk patients whose progression rates exceed guideline-based actionable thresholds for intensified careFRIENDSWOOD, Texas, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health th...

12/14/2025

https://www.biospace.com/press-releases/systematic-review-and-meta-analysis-confirms-tissuecypher-outperforms-traditional-pathology-or-clinical-factors-alone-to-identify-patients-at-increased-risk-of-developing-esophageal-cancer

Across multiple published studies, the test consistently identifies high-risk patients whose progression rates exceed guideline-based actionable thresholds for intensified care

12/12/2025

💕💕💕

12/12/2025

https://www.nature.com/articles/s41598-025-28903-9

Esophageal squamous cell carcinoma (ESCC) remains a leading cause of cancer-related mortality worldwide. Despite neoadjuvant concurrent chemoradiotherapy (nCCRT), approximately half of patients exhibit incomplete pathological response with persistent lymph node (LN) infiltration. The tumor microenvi...

12/11/2025

https://www.esocan.org/additional-resources/

EC Aware is listed as the first go-to when battling this horrific disease.

A selection of websites related to prevention and treatment of esophageal cancer, and support for persons with the cancer. Suggested risk calculators for lung, breast and colon cancers are at bottom of page.

12/11/2025

https://www.esocan.org/?ref=esocan-newsletter

Background and recent research on the epidemiology and prevention of esophageal cancer and Barrett's esophagus. Risk calculator estimates an individual's absolute risk.

12/10/2025

https://www.esocan.org/why-dont-we-get-counseling/?ref=esocan-newsletter

This article addresses an interesting question: why are Barrett's esophagus patients not offered specialist counseling in much the same way as persons carrying genetic mutations (e.g., BRCA1/2) that confer increased cancer risk? Dr. Davies examines the contrasting approaches in UK NICE guidelines re...

12/10/2025

https://www.esocan.org/oncogenetic-burden-of-obesity/?ref=esocan-newsletter

This article provides a mechanistic framework relating obesity to increased risk of a number of gastrointestinal cancers, including esophageal adenocarcinoma. It also highlights the potential of weight loss interventions (e.g., lifestyle, pharmacologic, surgical) to reduce GI cancer risk. The author...